Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02692251 2015-06-09
1
Nutritional compositions
The present invention is directed to a novel saccharide composition isolated
from yeast
culture. The invention is also directed to yeast cell based saccharide
composition with
increased water-solubility. The saccharide compositions disclosed in the
invention can be
used as nutritional or pharmaceutical additives or as part of nutritional or
pharmaceutical
composition in order to promote the health of animal or human subject to which
said
composition is administered. The invention is also directed to methods of
producing said
saccharide compositions.
BACKGROUND OF THE INVENTION
ProgutTM is whole yeast-based animal feed ingredient for maintaining good gut
health,
improving growth, and replacing antibiotics in most gastrointestinal problems
in animals (see
US 20020061345). ProgutTM is produced from whole brewery yeast (Saccharomyces
cerevisiae) and therefore it contains both yeast cell wall particles (mostly
mannoproteins and
13-glucans) and internal cell nucleotides. All these components have been
shown to be
important for the activity of ProgutTM.
The present invention reveals novel progut type products especially produced
with optimized
strong acid hydrolysis or enzymatic hydrolysis conditions or surprisingly
effective
combinations thereof to obtain novel bioactive and highly soluble product. It
was observed
that surprisingly strong acid treatment conditions, including very high acid
concentrations
including about 0.5 M to about 1 M acid and/or high reaction temperature in
range of 75- 100
degrees of Celsius, were needed to obtain increased solubilization and
obtaining highly
bioactive low molecular weight polysaccharides and oligosaccharides. The
conditions are
drastic and reveal high resistance of yeast materials to hydrolysis, however
there is optimum
with the conditions so that increase of acid to 2 M at high temperature causes
less effective
solubilization of the cell wall materials and/or increased amount of free
monosaccharides
caused by hydrolysis closing to total hydrolysis.
CA 02692251 2015-06-09
2
The unique chemical feature including high mannose oligosaccharide and low
starch
oligosaccharide content and high GlcP-saccharide content are related to high
bioactivity of the
novel saccharide fractions. These are clearly different from prior products
and competing
.. products. The optimal hydrolysis conditions to produce substantial amount
of effective
mannose oligosaccharides and GlcP-saccharides to same preparation is novel and
inventive
especially when the saccharides are produced to same preparation and from
yeast raw material
including native yeast without major hydrolytic or extraction chemical
treatments such as
fermentation derived yeast such as brewery process derived yeast.
It is realized that acid treatments of yeast materials in background are
mainly mild treatments
with low acid concentrations at modest pfl ranges and reaction temperatures,
are typically
used together with alkaline treatments to obtain mainly insoluble cell wall
preparations
referred as glucans. There is no evidence of glucan preparation acid derived
beta6
In this invention a set of old and new ProgutTM samples as well as the samples
from selected
related products are analyzed. The analysis is performed mainly by gel
permeation
chromatography, but the process uses NMR analysis of the soluble components
isolated here
by gel permeation chromatography.
Another aim of this study was to produce a new ProgutTM with increased
solubility and
without loosing its activity. This might be achieved by degrading the
mannoproteins and / or
p-glucans either enzymatically, mechanically, or by acid hydrolysis.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1. The amounts of soluble components in Progut-type product (PG) and
related
samples.
PG1-PG9, Progut-type product samples; related samples: Cl, Agrimos; C2,
Ascogen; C3,
Alphamune Alpharma; C4, Bio-Mos.
CA 02692251 2015-06-09
3
Fig. 2. Comparison of PG1 and PG2, from 0.2% solution. Gel permeation
chromatograms
of A. PG1 and B. PG2 water soluble components from 0.2% solutions (equal
sample
preparations); in SuperdexTM Peptide column (A214 was measured).
Fig. 3. Comparison of PG1 and PG2, from 1% solution. Gel permeation
chromatograms of
A. PG1 and B. PG2 water soluble components from 1% solutions (equal sample
preparations); in Superdex Peptide column (A214 was measured).
Fig. 4. Comparison of nine PG samples and related samples. Gel permeation
chromatograms of A. PG1, B. PG2, C. PG3, D. PG4, E. PG5, F. PG6, G. PG7, H.
PG8, I.
PG9, J. Cl, K. C2, L. C3, M. C4, water soluble components from 1% solutions
(equal sample
preparations); in Superdex Peptide column (A230 was measured). With PG9,
approximately
50% less material was analyzed. However, this is compensated by adjusting the
scale
accordingly in order to be able to compare the results equally.
Fig. 5. Comparison of five PG samples. Gel permeation chromatograms of A.
PG10, B.
PG1 1, C. PG12, D. PG13, E. PG14, water soluble components from 1% solutions
(equal
sample preparations); in Superdex Peptide column (A230 was measured).
Fig. 6. Comparison of PG samples generated from brewery yeast solution and its
homogenized version. Gel permeation chromatograms of acid hydrolyzed A.
brewery yeast
and B. homogenized brewery yeast water soluble components from 1% solutions
(equal
sample preparations); in Superdex Peptide column (A214 was measured).
Fig.7. Comparison of samples generated by enzymatic or chemical degradations
for
bacterial adhesion tests. Gel permeation chromatograms of A. Brewery yeast
(BY) +
glucanex (G), B. Homogenized BY (HBY) + G, C. BY G + savinase (S), D. HBY G+S,
E.
BY 1M H3PO4, F. HBY 1M H3PO4, G. BY G + pectinase (PE), H. HBY G+PE, I. PG1
PE, J.
PG1 + PR, water soluble components from 1% solutions (equal sample
preparations); in
CA 02692251 2015-06-09
4
Superdex Peptide column. A, B, and I are preparative chromatograms, where A230
was
measured (comparable with each other); the others were analytical, where A214
was measured
(comparable with each other).
Fig. 8. Comparison of PG1, water-soluble PG (PG WS), water-soluble PG with
emulgator (PG WS+E), and overhydrolyzed PG. Gel permeation chromatograms of A.
PG1, B. PG WS, C. PG WS+E and D. PG 15h water soluble components from 1%
solutions
(equal sample preparations); in Superdex Peptide column (A214 was measured).
Fig. 9. Effect of pronaseTM on Progut-type product samples. Progut-type
product samples
1 and 2 (PG1 and PG2) without (grey columns) and with (dark grey columns)
pronase
digestion.
Fig. 10. Effect of pronase on Progut-type product and brewery yeast solution.
Progut-
.. type product samples 1 and 2 (PG1 and PG2) without (grey columns) and with
(dark grey
columns) pronase digestion (second experiment). Brewery yeast (BY) was treated
either first
with pronase and then with acid hydrolysis (BY1) or first with acid hydrolysis
and then with
pronase (BY2), dark grey columns. As controls BY was hydrolyzed by acid with
the process
procedure (grey columns).
Fig. 11. Effect of savinaseTM on Progut-type product and brewery yeast
solution. Progut-
type product samples 1 and 2 (PG1 and PG2) without (grey columns) and with
(dark grey
columns) savinase digestion. Brewery yeast (BY) was treated either first with
savinase and
then with acid hydrolysis (BY1) or first by acid hydrolysis and then with
savinase (BY2),
dark grey columns. As controls BY1 and BY2 were hydrolyzed by acid with the
process
procedure (grey columns).
Fig. 12. Effect of pectinase on Progut-type product and brewery yeast
solution. Progut-
type product samples 1 and 2 (PG1 and PG2) without (grey columns) and with
(dark grey
columns) pectinase digestion. Brewery yeast (BY) was treated either first with
pectinase and
CA 02692251 2015-06-09
then with acid hydrolysis (BY1) or first by acid hydrolysis and then with
pectinase (BY2),
dark grey columns. As controls BY1 and BY2 were hydrolyzed by acid with the
process
procedure (grey columns).
5 .. Fig. 13. Effect of glucanexTM on brewery yeast solution. First
experiment, brewery yeast
with glucanex 5, 20, 100 mg at 30 C (GS 30C, G20 30C, G100 30C, respectively),
after
which the process acid treatment, dark grey columns. Second experiment,
brewery yeast with
20 mg of glucanex at 37 or 50 C (G20 37C, G20 50C, respectively), after which
the process
acid treatment, dark grey columns. As control, in both experiments the brewery
yeast was
treated only with the process acid treatment, grey columns.
Fig. 14. Combined effect of glucanex and savinase on brewery yeast solution.
A. Brewery yeast solution first with glucanex 5, 20, 100 mg at 30 C and then
with savinase 4
pd at 37 C (G 5+S, G 20+S, G 100+S, respectively), after which the process
acid treatment,
dark grey columns. B. Brewery yeast solution first with glucanex 20 mg at 37 C
and then
with savinase 4 or 20 pl at 37 C (G 37+S4, G 37+S20, respectively), dark grey
columns, or
with glucanex 20 mg at 50 C and then with savinase 4 or 20 pl at 37 C (G
50+S4, G 50+S20,
respectively), after which the process acid treatment, dark grey columns. As
controls for both
A. and B., brewery yeast solution was incubated without enzymes and treated
only with the
process acid treatment, grey columns.
Fig. 15. Combined effect of glucanex and endoglucanase and / or savinase on
brewery
yeast solution. Brewery yeast solution, with glucanex 20 mg and endoglucanase
200 lig at
37 C or 50 C (G 37+EG, G 50+EG, respectively) or first with glucanex 20 mg,
.. endoglucanase 200 lig at 37 C or 50 C and then with savinase 4 pl at 37 C
(G 37+EG+S, G
50+EG+S, respectively) followed by the process acid treatment, dark grey
columns. As
controls, brewery yeast solution was incubated without enzymes and treated
only with the
process acid treatment, grey columns.
CA 02692251 2015-06-09
6
Fig. 16. Effect of higher concentrations of H3PO4 combined with savinase
treatment on
brewery yeast solution. Acid hydrolysis of brewery yeast solution with
different 1-13PO4-
concentrations, 0.3M, 0.5M, 1M at 100 C (0.3M, 0.5M, 1M, respectively), dark
grey
columns. Incubation of brewery yeast solution with savinase (4 1), then acid
hydrolysis with
different H3PO4-concentrations, 0.3M, 0.5M, 1M, 2M at 80 C (0.3M+S, 0.5M+S,
1M+S,
respectively), dark grey columns. As controls, brewery yeast solution was
treated with the
process acid treatment, grey columns.
Fig. 17. Effect of HC1 on brewery yeast solution. Acid hydrolysis of brewery
yeast solution
with different HC1 concentrations, 0.3M, 0.5M, 1M, 2M at 80 C (0.3M, 0.5M, 1M,
2M
respectively), dark grey columns. As control, brewery yeast solution was
treated with the
process acid treatment, grey columns.
Fig. 18. Effect of H2SO4 on brewery yeast solution. Acid hydrolysis of brewery
yeast
solution with different H2SO4 concentrations, 0.3M, 0.5M, 1M, 2M at 80 C
(0.3M, 0.5M, 1M,
2M respectively), dark grey columns. As control, brewery yeast solution was
treated with the
process acid treatment, grey columns.
Fig. 19. Effect of homogenization. Brewery yeast solution was treated with
process acid
hydrolysis or 1 M H3PO4, and the homogenized brewery yeast solution was
treated with 1 M
H3PO4, at 80 C (BY, BY 1M, HBY 1M, respectively).
Fig. 20. Effect of homogenization with glucanex, savinase and pectinase.
Brewery yeast
solution (grey) and its homogenized version (dark grey), treated with
glucanex, glucanex and
savinase, and glucanex and pectinase (BY G, BY G+S, BY G+P, respectively),
followed by
process acid hydrolysis.
Fig. 21. Comparison between the solubilities of PG 1, PG 2, PG WS and PG WS+E.
CA 02692251 2015-06-09
7
Fig. 22. Comparison of PG1, PG-WS, Agrimos, Ascogen, Alphamune Alpharma, and
Bio-Mos by gel permeation chromatography. Samples from 1% solutions were run
in
Superdex Peptide column (A230 measured).
Fig. 23. Solubility of yeast products in water, measured from 1% solutions.
PG Av, ProgutTM average (n=9); PG S, Progut type Soluble product; Ag, Agrimos;
Al,
AlphamuneTM; BM, Bio-Mos
Fig. 24 shows the analytical GPC analysis of five Progut-type samples. This
analysis shows
that there is little variation in the GPC profile of the soluble material and
thus the production
process is well standardized.
Fig. 25. Analytical GPC analysis of PG, ProgutTM ; PG S, Progut type Soluble
product; and
PG WS, Progut type Water Soluble (totally (water)soluble product, further
processed from
Progut S).
Fig. 26. Comparison of the amounts of soluble poly- and oligosaccharides, as
well as
peptides. Relative amounts of material were measured as areas from gel-
permeation
chromatograms at the elution volume 6-14 ml, at 214 nm. PGAv refers to the
average area of
five different PG batches and is set to 1.
Fig. 27. GPC analysis of PG; PG S; Agrimos; AlphamuneTM; and Bio-Mos .
Fig. 28. Comparison of the amount of poly- and oligosaccharides and peptides
in Progut-type
materials and in three competitor products. PG Av, average (refers to the
average area of five
different PG batches and is set to 1); PG S; PG WS; Ag, Agrimos; Al, Alphamune
rm; BM,
Bio-Mos . The results are shown as relative amounts measured from gel-
permeation
chromatograms, at 230 nm, from 6-14 ml.
CA 02692251 2015-06-09
8
Fig. 29. Correlation of the amount of soluble middle-size material with the
bacterial adhesion
analysis results of five Progut-type product batches. Panel A. Relative
amounts of soluble
poly- and oligosaccharide -sized material as measured by GPC (Data from
preparative GPC
analysis of partially purified i.e. nearly amino acid/peptide free soluble
components from 400
mg of 1% PG solutions, measured at 230 nm, from 6-14 ml. Here the average area
from five
PG samples was 27800 mAu, it was given the value 1). Panel B. E. coli
bacterial adhesion
analysis results.
Fig. 30. Correlation of the soluble material amount with the bacterial
adhesion analysis results
of Progut-type product and competitor samples. Panel A. Relative amounts of
soluble poly-
and oligosaccharide -sized material. (Data from analytical, 1% sample, GPC
analysis of
partially purified i.e. nearly amino acid/peptide free soluble components from
400 mg of 1%
PG solutions, measured at 230 nm, from 6-14 ml. Here the average area from
five PG samples
was 205 mAu, it was given the value 1). Panel B. E. coli bacterial adhesion
analysis results.
Fig. 31. Mannose content of soluble poly- and oligosaccharide -sized material
(i.e. the soluble
components from 1% PG or related solutions isolated by GPC, Superdex Peptide
10/30
column, at 6-16 m1). PG Av, average (n=5) ; PG WS; Ag, Agrimos; Al,
AlphamuneTM; BM,
Bio-Mos
Fig. 32. Comparison of the mannose content with the bacterial adhesion
analysis results of
five Progut-type product batches. Panel A. Mannose content of soluble poly-
and
oligosaccharide -sized material (i.e. the soluble components from 1% PG
solutions isolated by
GPC, Superdex Peptide 10/30 column, at 6-16 m1). Panel B. E. coil bacterial
adhesion
analysis results.
Fig 33. 1HNMR of soluble poly- and oligosaccharides from Progut-type product.
Some
structural features of manno-oligosaccharides are indicated from the NMR-
spectrum.
Fig 34. Comparison of 1H NMR of PG and competitors.
CA 02692251 2015-06-09
9
DETAILED DESCRIPTION OF THE PRESENT INVENTION
Production of novel soluble brewery yeast derived product
The invention revealed novel methods for producing soluble therapeutic or
nutraceutical
products (food or feed products or additives thereof) from yeast, preferably
brewery yeast
type materials. The invention revealed several methods for production of the
materials
including specific hydrolytic and/or degradative methods
1) specific glycosidase, especially endoglycosidases
.. 2) protein cleaving enzymes such as proteases pronase and savinase,
3) improved chemical hydrolysis especially strong acid hydrolysis, and
4) physical homogenization of the raw material.
The invention is further directed combination of the methods with increasing
solubilization
activity.
Preferred raw material for producing the novel soluble product
The present invention is preferably directed to the use suitable yeast
materials especially yeast
form fermentation process, most preferably the brewery yeast as raw material
when the yeast
has been derived from brewing process. It is realized that such yeast material
would include
plant derived non-soluble materials, especially plant derived non-soluble
materials comprising
plant polysaccharides such as hemicellulose saccharides (as shown by cleavage
by pectinase)
and plant derived13-glucan materials such as cereal beta glucans, preferably
the cereal is
cereal used in brewing process, most preferably barley. It is realized that
the novel enzymatic
reactions are useful for the production additional amounts of cereal type
soluble saccharides
to the novel product.
It is realized that the novel saccharides produced by specific enzymatic
reactions or
alternatively by chemical methods have additional beneficial health effects.
CA 02692251 2015-06-09
It is further realized that the preferred soluble combinations can be produced
by combining
for raw materials
1) yeasts not used in brewing and
2) plant derived polysaccharides preferably plant polysaccharides such as
hemicellulose
5 polysaccharides and/or plant glucans especially cereal, and most
preferably barley
derived polysaccharides or cereal glucans, most preferably barley glucan.
Preferred process
The preferred optimized process includes at least following steps
10 1. Providing brewery yeast raw material
2. Hydrolysis by enzyme and/or by optimized acid hydrolysis
The invention is further directed to process comprising steps:
1. Providing brewery yeast raw material
2. Physical homogenization of the material
3. Hydrolysis by enzyme and/or acid, in a preferred embodiment by acid
The invention is further directed to process comprising steps:
1. Providing brewery yeast raw material
2. Physical homogenization of the material
3. Hydrolysis by enzyme and acid
Novel oligosaccharide and low molecular weight polysaccharide compositions
The novel degradative production processes gave product which has increased
solubility or
less non-soluble material. Beside the increased solubility the materials have
increased
biological activities against diarrhea causing infections and activity to
increase the growth of
animals.
Isolation of the soluble component from novel product
CA 02692251 2015-06-09
11
The invention is especially directed to the separation of the novel soluble
fraction produced
from the brewery yeast materials.
Preferred oligosaccharide compositions in the product
The inventors analyzed the biological activities of the novel soluble products
from the profiles
of Superdex Peptide chromatograms (1% solutions in water). The absorbance
indicates the
relative amounts of the soluble different size components.
The relative effectivity of Progut-type product in biological models and
related material could
be presented in numbers by calculating the elution areas (e.g. Table 1). The
invention revealed
novel soluble saccharide preparations referred as "Soluble" and "Water
soluble" materials
useful for the inhition of harmful bacterial activity such as diarrhea causing
E. coli activities.
It is realized that such preparations are useful for growth and well-being of
human and
animals.
Preferred product types
It is realized that the novel hydrolysis process produced novel soluble
saccharides which can
be used as such as non-fractionated composition derived from the yeast. The
preparation is in
preferred embodiment neutralized or partly neutralized, preferably by strong
alkaline such as
sodium hydroxide. In a preferred embodiment the product is dried, e.g by spray
dying, drum
drying or other known drying methods.
The invention is further directed to fractionated products including partially
fractionated and
purified saccharide products. Preferred partial purification methods includes
removal of part
of major non-saccharide components such as 1) desalting, in preferred
embodiment by
precipitation of salt such as precipitation of phosphate by Calsium or other
ions, 2) removal of
ionic molecules or hydrophobic molecules by specific adsobents such as
hydrophophic or ion
exchange matrixes and/or 3) removal of the non-soluble material or part of it.
It is realized
that the partial purification increase the novel saccharide content of the
preparation typically
by 10-30 % or even 50 %. Desalting after strong phosphoric acid hydrolysis
would increase
the amount of saccahrides in preparation enven by 30-60 %, thus increasing the
preferred
CA 02692251 2015-06-09
12
amounts of preferred Mana3Man- mannose saccharides from from about 15, more
preferably
20 g/ kg to about 20 g/kg and more preferably 30 g /kg.
Preferred purification methods includes isolation of the saccharide fraction
or part of it. The
content of the saccharides in the purified fraction is preferably at least 10
% more preferably
at least 25 % even more preferably at least about 50 %. The gel filtration
fractions measured
in NMR are estimated to include saccharide purities of at least 60 %, even
more preferably at
least 70 %. It is realized that similar purities can be reached by other
standard purification and
fractionation methods.
Preferred sizes of the saccharide materials
The invention revealed two preferred major size ranges of the soluble products
large size
products eluting from 6 to 12 min from the Superdex Peptide column and
intermediate size
product eluting from about 12 minutes to about 16 minutes.
The invention is especially directed to the saccharide fractions described,
which contains
novel useful saccharides and correlate with the improved increased biological
activity of the
product.
Preferred soluble polysaccharide sizes and fractions
The product comprises a peak at void corresponding to saccharides with size
from about 20 to
about 30 Hexose (Hex) units of gel filtration size and to possible larger
soluble
polysaccharides. More preferably the void from about 7.7 minutes corresponds
to soluble
polysaccharides about 25 hexose unit saccharides and larger. The invention is
directed to
novel products comprising high amount of soluble polysaccharide materials,
which was a
characteristic for the novel products. Preferred polysaccharide fractions
includes fraction
eluting from 6-9 minutes corresponding to saccharides of about 20 hexose units
and larger
from the Superdex Peptide column and 6-12 minutes.
It is realized that the elution position at 12 min is about at border of
oligosaccharides (DP10)
and polysaccharides comprising more than 10 monosaccharide residues.
CA 02692251 2015-06-09
13
The invention is thus directed to the polysaccharide fractions
a)from 10 to 30-mers or gel filtration size from 10 to at least about 30-Hex
units and larger
soluble polysaccharides
b) from 20 to 30-mers or gel filtration size from 20 to at least about 30-Hex
units produced by
.. the processes according to the invention.
Preferred intermediate size product
The invention is further directed to preferred intermediate size product
eluting from about 12
minutes to about 16 minutes. This range corresponds oligosaccharides from
about
di/trisaccharides to about decasaccharides or saccharides with gel filtration
size from 3 to at
least about 10-Hex units.
Preferred larger oligosaccharide and polysaccharide fraction
The invention is further directed to combination fraction of larger
oligosaccharides an
polysaccharides eluting from about 6 minutes to 14 minutes. This preferred
fraction contain
oligosaccharides from about 4-6-mers, more preferably from about 5-6-mer to
polyasaccharides at least about 20-30 mers or
to gel filtration size from 5 to at least about 30-Hex units and larger
soluble polysaccharides.
In gel filtration two hexose (such as glucose, mannose or galactose) units
correspond typically
to one HexNAc (e.g. GlcNAc or GaINAc) in oligosaccharide or polysaccharide and
expected
elution size of a saccharide can be calculated typically from the amount of
Hex unit.
Homogenization of the raw material and combination with hydrolysis
.. It was revealed that homogenization of brewery yeast solution before
process acid hydrolysis
increases the solubility of Progut-type product-type product by 15%, with
brewery yeast raw
material and more acid even more.
The invention is especially directed to processes including homogenization
before
hydrolysis,in a preferred embodiment acid hydrolysis.
CA 02692251 2015-06-09
14
Enzymatic treatments increase the solubility of acid hydrolysis product (PG)
The invention revealed that product hydrolyzed by acid can be further
solubilized by
enzymatic treatment with protease or polysaccharide cleaving enzymes. The
preferred
enzymatic treatment includes Pronase, Savinase, Pectinase, Glucanex and
Glucanex combined
with savinase or enzymes with specificity for the same protein or
polysaccharide type.
Enzymatic treatment before acid hydrolysis
The invention revealed that product hydrolyzed by acid is more soluble if
enzymatically
treated with protease or polysaccharide cleaving enzymes before the acid
hydrolysis. The
preferred enzymatic treatment includes Pronase, Savinase, Pectinase, Glucanex
and Glucanex
combined with savinase, and englucanase enzyme optionally combined with
savinase or
enzymes with specificity for the same protein or polysaccharide type.
Optimized acid hydrolysis conditions
The invention is directed to optimized acid hydrolysis conditions for
producing the novel
soluble product.
The invention revealed that acid treatments with increasing amounts of acid
increase the
solubility to brewery yeast.
The invention is especially directed to optimized hydrolysis processes wherein
the amount of
the raw yeast material calculated as dry weight is between 5-35 weight/volume
(w/v) % of the
reaction total volume, more preferably between 10- 30 % (w/v), even more
preferably 15 -25
% (w/v) and most preferably about 20 % (w/v) of the reaction total volume.
The present invention is directed to hydrolysis conditions optimized with
regard to time,
temperature, acid concentration (/amount of acid per amount of sample), and
type of acid.
Preferred acid includes inorganic acids phosphoric acid (H3PO4), hydrochloric
acid and
sulphuric acid. Most preferred acid is phosphoric acid (H3PO4).
CA 02692251 2015-06-09
The present invention reveals novel progut type products especially produced
with optimized
strong acid hydrolysis or enzymatic hydrolysis conditions or surprisingly
effective
combinations thereof to obtain novel bioactive and soluble product. It was
observed that
surprisingly strong acid treatment conditions, including very high acid
concentrations
5 including about 0.5 M to about 1 M acid and/or high reaction temperature
in range of 75- 100
degrees of Celsius, were needed to obtain increased solubilization and
obtaining highly
bioactive low molecular weight polysaccharides and oligosaccharides. The
conditions are
drastic and reveal high resistance of yeast materials to hydrolysis, however
there is optimum
with the conditions so that increase of acid to 2 M at high temperature causes
less effective
10 solubilization of the cell wall materials and/or increased amount of
free monosaccharides
caused by hydrolysis closing to total hydrolysis.
Optimized hydrolysis by H3PO4
The invention is preferably directed to the use of phosphoric acid (H3PO4)
with concentrations
15 .. above 0.5 M more preferably above about 0,75 M and even more preferably
above 1 M or
most preferably with about 1M.
The effect of solubilization was reduced with 2 M phosphoric acid even below
the effect of
0.5 M, the extreme acid concentration surprising did not increase the
hydrolysis but caused
precipitation of the material. This indicates that the optimum acid
concentration is from about
0.5 M to about 1 M for effective solubilization.
In a preferred embodiment about 1 M H3PO4 is used as optimal concentration,
the preferred
range is from about 0.75 M to about 1.25 M , even more preferably from about
0.8 M to about
1.2 M and most preferably about 0.9 M to about 1.1 M, when the reaction is
performed at
temperature about 80 degrees of Celsius (preferably between 70-100 degrees of
Celsius, even
more preferably between 70 and 95 degrees of Celsius even more preferably
between 75 and
85 degrees of Celsius. The preferred reaction time is about 4 hours,
preferably from 2 to 8
hours, more preferably 3 to 5 hours, most preferably from 3.5 to 4.5 hours.
The invention is especially directed to strong hydrolysis conditions or
combination of strong
acid hydrolysis conditions and enzymatic hydrolysis to obtain increased amount
of highly
CA 02692251 2015-06-09
16
soluble and bioactive saccharides according to the invention, in a preferred
embodiment
hydrolysis condition equivalent of present invention are used.
In a preferred embodiment the conditions are equivalent of about 1 M 113PO4
for 4 hours at
about 75 to 90 degrees of Celsius for about 4 hours. It realized if
temperature is increased the
.. amount of acid and/or reaction time can be decreased and vice versa. In
another preferred
embodiment the temperature is increased from about 90 to about 100 degrees of
Celsius and
the amount of acid is from about 0.5 M to about 1 M and the reaction time is
about 4 hours.
The figure 16 shows high solubilization at 100 degrees with 0.5 and 1 M acid.
It is further realized that the highly soluble and bioactive product can be
obtained by using an
ezyme according to the invention or an enzyme in combination with the acid
hydrolysis, such
as shown in Figure 16 for savinase enzyme. The use of enzyme enhances the
solubilization
process so that lower acid concentration, reaction temperature or reaction
time is needed. The
invention is in a preferred embodiment directed to use of an enzyme according
to the
invention in combination with 0.3- 1 M acid.
Optimized hydrolysis by hydrochloric acid HC1
The invention is preferably directed to the use of HC1 with concentrations
above 0.5 M more
preferably above about 0.75 M and even more preferably above or about 1M. The
2 M acid
produces higher solubilization but also increased amount of monosaccharides as
the acid
hydrolysis conditions with the very strong mineral acid approaches total
hydrolysis
conditions.
In a preferred embodiment about HC1 is used as optimal concentration, the
preferred range is
from about 0.75 M to about 1.25 M , even more preferably from about 0.8 M to
about 1.2 M
and most preferably about 0.9 M to about 1.1 M, when the reaction is performed
at
temperature about 80 degrees of Celsius (preferably between 70-90 degrees of
Celsius, even
more preferably between 75 and 85 degrees of Celsius. The preferred reaction
time is about 4
hours, preferably from 2 to 8 hours, more preferably 3 to 5 hours, most
preferably from a 3.5
to 4.5 hours.
CA 02692251 2015-06-09
17
The invention is further directed to use of H2SO4 at increased concentrations
above 0.5 M and
at about 1 M as described above for other acid treatments. The data shows that
2 M acid does
not produce increased solubilization, possibly indicating increased
precipitation.
Combinations of the solubilization methods
The invention further revealed multiple useful combinations of the methods as
described in
the experimental section. Preferred combinations includes homogenization with
enzymatic or
chemical hydrolysis.
In a preferred embodiment the invention is directed to the combinations of the
methods such
as homogenization and improved chemical hydrolysis. This method is preferred
to because of
high efficiency in solubilization of the product and low costs of the methods
and reagents.
The invention is further directed to the combination of the homogenization
with enzymatic
hydrolysis by glycosidases and/protein cleaving enzymes.
The invention further revealed preferred combinations of enzymatic cleavage of
proteins and
glycosidase cleavage producing high yields of materials. The method is
preferably combined
with homogenization.
The invention further revealed preferred combinations of chemical cleavage
methods with
enzymatic cleavage of proteins and/or glycosidase cleavage producing high
yields of
materials. The method is preferably combined with homogenization.
Improved activities of soluble carbohydrates produced
The invention revealed that the preferred solubilization methods produced
increased amounts
of soluble molecular materials with useful biological activities. The
invention is especially
directed to increased activities against pathogenic microbes such as diarrhea
causing
microbes, especially bacteria including E. coli.
CA 02692251 2015-06-09
18
Preferred enzymatic treatments
Preferred endoglycosidases
Cleavage of glucose polysaccharides
The invention revealed that glucose polysaccharide cleaving enzymes are useful
in the
production of the novel soluble product.
In a preferred embodiment f3-linked glucose polysaccharide cleaving endo-3-
glucosidase
enzymes such as endo-glucosidase and glucanex comprising cellulase activities
have useful
activities in reducing the insoluble material in the novel production process.
The invention is
especially directed to cleaving cellulose type and beta-glucan
polysaccharides. The preferred
3-glucans to be cleaved are G1e134G1c-structure comprising 3-glucans such as
cellulose, cerial
b-glucans including 34 and 33-linkages between the glucose residues. The
preferred endo-3-
glucosidase are endo-glucosidases and cellulases.
The invention is especially directed to the cleavage of residual non-soluble 3-
glucans such as
yeast cell wall glucan, cereal glucan and/or cellulose material in the brewery
yeast material, in
a preferred embodiment in order to produce higher solubility and/or in order
to produce
soluble bioactive glucan oligosaccharides.
The invention is especially directed to the production of cellulose and/or
cereal 3-glucan
oligosaccharides comprising structures according to the
Formula
[G1c34]G1c-structures,
Wherein n is an integer from 2-20, more preferably 2-10,
The invention is more preferably directed to the production of cereal type
glucan
oligosaccharide to the product. Preferrably the product comprises 34 and 33-
linkages between
the glucose residues according to the
Formula
CA 02692251 2015-06-09
19
[G1c1341 [G1c133],2[G1c134],3G1c133 [G1c1341,-,4G1c-structures,
Wherein nl, n3, and n4 are integers from 0 to about 5, preferably 1 to 4 even
more preferably
1 to 3, independently
And
.. n2 is 0 or 1
The invention is especially directed to the endo-P-glucosidase catalyzed
production of the
glucan oligosaccharides
The invention revealed presence of a-linked glucose materials in the preferred
fractions
according to the invention. The invention is further directed to use of endo-a-
glucosidases in
production of the novel soluble product. The a-glucose polysaccharide cleaving
enzymes are
especially preferred adjustment and optimization of novel product composition
and preferred
as additional enzymes with endo-a-glucosidase activity especially endo-a4-
glucosidase
activity, preferably starch or amylose cleaving enzyme.
Cleavage of pectin and related hemicellulose materials
The invention is further directed to the treatment of the brewery yeast
material by a pectinase
enzyme preparation. It is realized that the pectinases have reported to
comprise multiple
activities. The invention is directed to cleavage of pectin and/or other
hemicellulose type
materials, such as pectin comprising hemicellulose materials by pectinase
enzyme comprising
preparations.
In a preferred embodiment the invention is directed to the production of
pectin and or
hemicellulose derived oligosaccharides or low molecular weight soluble
polysaccharides to
.. the product.
Preferred protease treatments
The invention is directed to use of protease to cleave protein materials from
the raw material
or acid hyrolyzed material. Preferred proteases are savinase or pronase.
CA 02692251 2015-06-09
Novel glycan comprising materials with improved solubility,
Progut type product Soluble and Progut type product Water soluble
The present invention revealed that it is possible to produce an acid
hydrolysed yeast
preparation with increased water solubility by the optimized methods according
to the
5 invention. It is realized, that the highly soluble material is useful for
more effective
formulation of feed and foods. The soluble fraction is especially preferred
for liquid feed and
liquid food or food additives, especially drinks and beverages. It is realized
that material with
much less than 50 % of soluble material are not useful for liquid foods or
beverages due to
practical reasons, such as bottling and transferring the liquid materials in
production, and
10 practical material should preferably have well over 50 % of soluble
material. It is realized that
some applications would tolerate partially insoluble materials and minor part
of insoluble
material is in a preferred embodiment used in food compositions as fiber to
support nutrition
and health. The total solubilities of Progut type product and Soluble version
thereof in
comparison of some reference products used in animal feed are represented in
Figure 23.
The novel soluble products comprise even higher amount of soluble saccharide
materials
(oligosaccharides and polysaccharides) with improved biological activity. The
amounts of
soluble poly-and oligosaccharide materials (eluting between 6-14 min from the
Superdex
Peptide column, as shown in Fig. 25) are represented in Figs. 26 and 28. The
amount of
oligosaccharides in Progut type product Soluble and Progut type product Water
Soluble was
about 2-higher and even over 3-times higher, respectively than less optimized
Progut type
product.
Preferred solubility ranges of the novel soluble materials
The invention is especially directed to novel Progut type product Soluble,
wherein the total
solubility as 1 % water solution is over 55 %, more preferably over 60 %, even
more
preferably over 65 %, even more preferably over 63 %, even more preferably
over 66 %, even
more preferably over 67 %, and most preferably over 68 %. In a preferred
embodiment the
water solubility is about 70 %, preferably in range 55 % to 85%, more
preferably in range 60
CA 02692251 2015-06-09
21
Vo to 80%, more preferably in range 63 % to 77 %, more preferably in range 65
% to 75%,
even more preferably in range 66 % to 74%, even more preferably in range 67 %
to 73%.
The invention is further directed to practically completely water soluble
saccharide
comprising products, wherein the water soluble product has practically
complete water
solubility as 1 % (weight/volume) water solution at room temperature
(preferably between 20-
25 degrees of Celsius). The preferred water soluble fraction is isolated from
the Progut type
product, preferably Progut type product Soluble.
The preferred complete water solubility is at least 90 % or over 90 %, more
preferably over
93 %, even more preferably over 95 %, even more preferably over 96 %, even
more
preferably over 97 %, and most preferably over 98 %.
The invention is further directed to Progut type product Semi Water Soluble,
wherein the non-
soluble materials are partially removed. It is realized that low partial
removal provides
material similar to the Soluble product and high removal similar to Water
Soluble product. In
a preferred embodiment a the non-soluble components may be removed in varying
extent
from about 10 % to about 80 %, more preferably from about 20 % to about 75 %,
more
preferably from about 25 % to about to about 66 %, even more preferably from
about 33 % to
about to about 66 % obtain the Semi Water Soluble product. The total
solubility of the Semi
Water Soluble product is preferably, within range from about 73 % to about 94
%, more
preferably from about 76 % to about 92.5 %, even more preferably from about 80
% to about
90 %, and even more preferably from about 81 % to about 89 %. In a preferred
embodiment
the solubility is close to about 80 %, preferably within range from about 75
and to about 85
%, or close to about 90 %, within range from about 85 % to about 95 %. The
total solubility
of the Semi Water soluble fraction is preferably adjusted to cover the
solubilities between the
Soluble and Water Soluble fraction/materials.
The word about indicates preferably in preferred embodiments within 2 % units
of the value,
and more preferably within 1%, or more preferably within 0.5 % units from the
exact value or
in separate embodiment exactly the value.
CA 02692251 2015-06-09
22
Biologically active carbohydrate components
The invention further revealed that novel material with improved solubility
has improved
biological activity against diarrhea causing bacteria. This is shown in Fig.29
and in
comparison to related materials in Fig. 30 panel B. The biological activity
correlates with the
presence of UV absorbing materials. The materials were deproteinized and
hydrophobic
impurities were removed and did not contain major impurities in the
oligosaccharide range
observable by NMR. Therefore the absorbance appears to correspond to the
carbohydrate
materials, saccharides including water soluble oligo- and polysaccharides,
partially due to
reducing end aldehyde absorbance and reducing end derivatizations formed in
the process and
minor amount of GlcNAc residues linked to saccharides. Minor amount of peptide
materials
are likely included as indicated in figure legends, but based on NMR the
quantitative
importance of these is limited.
Active carbohydrate components
Mannose saccharides
Analysis shown in Fig. 31 reveals that new highly active soluble Progut type
products
includes increased amounts of mannose oligosaccharides. The Figure 32 shows
that the
biological activities of the fractions correlates partially with mannose
content. The inventors
were able to define by NMR-analysis novel highly active mannose
oligosaccharides and
polysaccharides in Progut type products. The increase of this type of
oligosaccharides is
especially useful for novel nutraceutical molecules. The mannose content was
increased by
about 50 % in the novel soluble products.
Preferred terminal Man a3-structures
The invention revealed further that beside the mannose content the higher
activity of the
Progut type products (e.g. as shown in Fig. 30) is explained by specific
structures of mannose
oligosaccharides. The invention is especially directed to oligosaccharide
sequences
comprising increased amount of terminal Mana3-structures as shown in figures
33-34. The
invention further revealed distinct amount of non-reducing end terminal and 3-
substitud
CA 02692251 2015-06-09
23
Mana2-epitopes and midchain Manct2-epitopes in linear Mana2-structures, which
are key
parts of the mannose saccharides derived from yeast.
The invention is preferably directed to the increased terminal Mana3-
structures, more
preferably non-reducing end terminal Mana3Mana2 comprising oligosaccharides
produced
by the process according to the present invention and in a preferred
embodiment produced
from brewery yeast. In a preferred embodiment the amount of terminal Mana3-
structures
yields NMR signal, which is larger than the NMR signal of non-reducing end
terminal and 3-
substitud Mana2-epitopes or larger than the NMR signal of midchain Mana2-
epitopes in
linear Mana2-structures as indicated in Figures 33-34. In a preferred
embodiment the Mana3-
signal is higher than either one of the Mana2-epitope signals marked in Fig.
33 in proton
NMR spectroscopy as indicated in Figures 33 and 34. The invention is
especially directed to
the Mana3-glycans, wherein the proton NMR signal at Mana3-position is at least
5 % higher,
more preferably at least 7 % higher, even more preferably 9, and most
preferably at least 10 %
higher that the comparative Mana2-signal indicated in Fig. 33.
It is understood that the terminal non-reducing end Mana3Mana2 structures are
novel active
components to be directed for inhibition of pathogens, especially
diarrheagenic bacteria such
as E. coli. The reducing end Mana2-structure gives the glycan novel
conformation. The
activity of this glycan can not be known based other glycans such as
Mana3Manf34G1cNAc
structures or reducing disaccharide epitopes.
The present invention is further directed to the terminal Mana3 enriched
saccharide fractions
comprising at least about 10 grams, even more preferably at least 15 grams/kg,
even more
preferably at least 16 grams, even more preferably at least 17 grams, even
more preferably at
least 18 grams, even more preferably at least 19 grams, even more preferably
at least 20
grams, even more preferably at least 21 grams, even more preferably at least
22 grams, and
most preferably at least 23 or 24 gram per kg of the preferred mannose
oligosaccharides. The
preferred mannose oligosaccharide includes oligosaccharides comprising
mannose, preferably
CA 02692251 2015-06-09
24
mainly mannose, but which may further comprise other monosaccharide residues
preferably
Glc, or GlcNAc or GleN, preferably as minor components.
Other active carbohydrate components, special 13-glucosaccharide signals
The inventor observed special P.-glucose oligosaccharide signals at region of
about 4.51- 4.53
ppm in proton NMR-spectrum. These are associated novel unusual low molecular
weight
glucose oligosaccharide and polysaccharide signals. The invention is
especially directed to the
oligosaccharides enriched with 136-linked glucose saccharide having
characteristic signals in
the region (gentiobiose H1 of Glc(36 is at about 4.51 ppm, signals of midchain
Glcf36 residues
are at about 4,519; 4,529; and 4.523 ppm; Lo V.M. et al. Carbohydr Res. (1993)
245, 333-
345).
The invention is further directed to saccharide materials according to the
invention, when the
material further comprise minor amount of GlcN/G1cNAc, preferably the
materials are Glc13-
materials derived from yeast and more preferably comprise Glc136 residues.
The invention is in separate embodiment further directed to 134-linked glucose
oligosaccharides, when the yeast raw material is cultivated in
(cereal)133/4glucan or cellulose
containing materials, the preferred 13(3/)4glucose saccharide signals are in
the preferred region
(e.g. 133/4g1ucan oligosaccharides have 134-linked Glc H1 signals at about
4.53 ppm).
The amount of glucose materials is comparable to mannose materials in the
sample based on
monosaccharide analysis, part of the Glc materials includes Gloa-materials but
both alpha and
beta signals correspond to substantial amount of saccharides.
Prefererred enriched oligosaccharides according to the invention
The invention is directed to the preferred saccharides according to the
invention, wherein the
signals are especially from oligosaccharides due to sharpness of the NMR-
signals of the
Progut type products. The oligosaccharides according to the invention have
degree of
CA 02692251 2015-06-09
oligomerization between 2-10. It is realized that most of the background is
directed to
polysaccharide materials such as glucans, and large polysaccharides which are
insoluble.
Total saccharide content and larger saccharide content
5
Quantitation of larger oligosaccharides and poly saccharides by UV absorbance
The invention is directed to novel Progut type products with specific larger
oligosaccharide
and polysaccharide content.
10 Sample of 0.4 grams of dry Progut type product or relative product was
diluted in water as 1
% solution (weight/volume). Sample was centrifuged and water soluble fraction
was dried and
taken for further analysis. The oligosaccharide and polysaccharide fraction
was further
purified by removing proteins and peptides and lipophilic impurities by
incubating with 1.4
ml DowexTM H+-resin and bond elut column (analysis, experimental section).
15 The purified sample dried in vacuum centrifuge and soluted in 1000
microliters of water. 15
microliter sample of the 1000 microlitres was run in Superdex peptide column
and absorbance
area from 6 to 14 min was collected at 214 nm. The standardized Progut type
product gave
680 mAU (absorbance units) in range of larger saccharides eluting between 6-14
min from the
column (containing larger oligosaccharides and polysaccharides).
The invention is specifically directed to novel Progut type products,
especially soluble and
water soluble product, which give higher than 680 mAU (Abs units, absorbance
units) as
absorbance integral between 6-14 min per 6 mg of original dry sample, when run
in Superdex
peptide column (Amersham Pharmacia, Analysis Examples) with flow rate 1.0
ml/min, when
the saccharide fraction essentially purified from contaminating peptides and
proteins from the
saccharide fraction. The invention is also directed to equivalent
oligosaccharide fractions with
corresponding material size range in gel filtration and material produced by
process according
to the invention. The preferred values for the absorbance integral are 1.3
times, more
preferably 1.5 times, even more preferably 1.7 times, even more preferably 1.8
times, even
more preferably 2.0 times, even more preferably 2.3 times, even more
preferably 2.5 times,
CA 02692251 2015-06-09
26
even more preferably 2.7 times, even more preferably 2.8 times, and most
preferably
preferably 2.9 times, 3.0 times or 3.2 times the 680 mAU.
Quantitation of oligosaccharides and polysaccharides by Mannose mass
The invention is directed to novel Progut type products with specific total
oligosaccharide and
polysaccharide content. This was done by analyzing the total mannose content
in the
oligosaccharide and/or polysaccharide fraction eluting between 6 to 16 min
from Superdex
peptide column.
Purification or isolation of soluble saccharide materials
The present invention is especially directed to purified or enriched fractions
comprising one
or several of the preferred saccharide types according to the invention. It is
realized that the
enriched or purified fractions have especially high specific activity as
nutraceuticals
functional foods or feed or nutraceutical (food or feed) additives.
The preferred purification methods include following and combinations thereof
a) chromatographic methods such as
i. chromatographies for absorption of charged and or
lipopholic
(hydrophobic impurities)
ii. size exclusion chromatography, especially gel filtration to remove low
molecular weight impurities
iii. affinity chromatographies with matrices binding to the saccharides or
part thereof, preferably chromatography on activated carbon
and/or
b) Phase separation solution methods such as extraction with solvents and/or
precipitation of impurities or saccharides. In a preferred embodiment organic
solvent is used for precipitation, preferably an alcohol or ketone such as
methanol or ethanol, more preferably ethanol; or acetone is used for
precipitation of the saccharides of preferred size.
and/or
CA 02692251 2015-06-09
27
c) Centrifugation and separation of solution and precipitant
and/or
d) Chemical or enzymatic methods to degrade undesired components, preferably
mild alkaline hydrolysis to degrade alkaline labile impurities and/or
enzymatic
hydrolysis of GIca-comprising glycogen/starch type saccharides
The invention is further especially directed to the ion exchange and/or
hydrophobic
chromatographies for removal of impurities and/or size exclusion
chromatographies for the
purification of the novel saccharide fraction. It is realized that ion
exchange in a preferred
embodiment cation exchange resin material also absorb lipophilic compounds or
both
matrixes may be included in the same column.
Solubility experiments
Figures 9-21 show solubilities product fraction after acid and/or enzyme
treatments. The
remaining insoluble material in 0.2 % water solutions was measured. The
amounts shown
corresponds to100 mg of original dry product in 50 ml. The mg amounts
indicated thus
correspond to % of insoluble materials. In figure 23 the amount of soluble
material is
indicated as %.
EXPERIMENTAL SECTION
Abbreviations
BY Brewery yeast
HBY Homogenized brewery yeast
G Glucanex
PG Progut-type product
PG S Soluble Progut-type product
PG WS Water-soluble Progut-type product
PG WS+E Water-soluble Progut-type product with emulgator
CA 02692251 2015-06-09
28
PE Pectinase
PR Pronase
Savinase
EXAMPLE 1
Materials and Methods
Materials
ProgutTM (PG) samples from Suomen Rehu
Fourteen ProgutTM type product samples from different production batches: PG1-
PG14. Three
Progut-type product samples from different production processes: PG 15h,
hydrolyzed for 15
h; PG WS, PG water soluble; PG WS E+, PG water soluble with emulgator.
PG1 has been shown to work well, whereas PG2 was not as effective as indicated
on bacterial
adhesion assays. PG4 gave good results on the field when tested with goats.
Commercial samples from other producers
Agrimos (Cl), and Ascogen (C2), Alphamune alpharma (C3), and Bio-Mos (C4).
Whole brewery yeast samples
Brewery yeas, BY and homogenized brewery yeast, HBY.
Procedure of analysis
Preparation of the sample
Either 0.2% water solutions or 1% water solutions were prepared from Progut-
type product
and related samples. These were incubated at room temperature for 2-5 hours
under gentle
mixing. The mixtures were then centrifuged (4000 rpm for 20 min), the
supernatant was
lyophilized, and the dry weight was measured.
CA 02692251 2015-06-09
29
Analysis of the soluble components
The soluble components of the samples were purified by two purification steps
before gel
permeation chromatography: First, the dry material was diluted into a slurry
solution of Ht.
beads (AG 50W-X8 resin, Bio-Rad, 1.4 ml for 0.4 g sample) and incubated in
gentle mixing
at RT for 2 hours. Second, the supernatant from Fr-bead solution was eluted
through
BondElut C-18 -column (500 mg / 6 ml, Varian). After concentration the samples
were run in
gel permeation chromatography in a column of Superdex Peptide 10/300 GL
(Amersham
Biosciences), with 50 mM ammoniumbicarbonate, at flow rate 1 ml / min,
measuring the
absorbance at 214 or 230 nm, in Akta Purifier 10 (Pump P-903, UV-900, Amersham
Biosciences). Superdex Peptide column: Void volume, 6.7 ml; total elution
volume, 18.0 ml;
and elution of poly/oligo/monosaccharides: At void volume 30 Hex units; at 7.7
ml 25 Hex
units; at 14.4 ml five Hex units; at 16.7 ml two Hex units, and at 17.3 ml one
Hex unit.
Nuclear magnetic resonance spectroscopy (NMR)
For NMR analysis samples were collected from Superdex Peptide chromatography
as follows:
Large size components (elution from 6 to 12 ml) and intermediate size
components (elution
from 12 to 16 m1). Prior to one dimensional 'H NMR experiments the samples
were first
lyophilized from and then dissolved in D20 (99,9%). The NMR spectra were
recorded by
Varian Unity 500 spectrometer (Varian Inc.) at 23 C.
Acid hydrolysis of the brewery yeast
The acid hydrolysis of the whole brewery yeast -solution with 113PO4 is
similar to the
hydrolysis used in Progut-type product manufacturing process: pH is adjusted
to 2.4 by
H3PO4 (concentrated, 87%), and incubated at 80 C for four hours. This acid
hydrolysis is
referred hereinafter as 'process acid hydrolysis' in text.
CA 02692251 2015-06-09
Results
Comparison of the amounts of the soluble components
1% solutions of nine Progut-type product samples and four related samples were
prepared and
the dry weights of the water-soluble components were measured (Fig. 1). From
the results
5 shown in Fig. 1 it can be concluded, that approximately 50% of the Progut-
type product
material is water-soluble, although the solubility varies depending on the
batch. Alphamune
alpharma (C3), Bio-Mos (C4), and Agrimos (Cl) have less soluble components
than Progut-
type product. On the other hand, Ascogen (C2) seems to have a good solubility.
10 However, it should be noticed that in these lyophilized samples may be
left variable amounts
of water. Therefore, error in dry weights might be higher than on average.
Comparison of the soluble materials by gel permeation chromatography
Chromatograms from 0.2% solutions
15 Comparison of PG 1 and 2
0.2% solutions of PG1 and PG2 were prepared as described in Materials and
Methods, and the
chromatograms of the soluble material are shown in Fig. 2. Comparing the
soluble materials
of PG1 and 2 can be seen that PG1 has relatively more intermediate sized
material (elution
between 12-16 ml) than PG2 and, on the contrary, PG2 has more large size
material (elution
20 between 6-12 ml) than PG1. The overall amount of soluble material seems
to be higher in
PG1 than PG2 as indicated by the higher absorbtivity in PG1. The same
phenomenon can be
pointed out also from Fig. 1.
These differences in solubility and chromatographic behavior imply the
effectivity of PG1
and PG2: PG1 and PG2 have been tested by bacterial adhesion tests and PG1 was
shown to be
25 effective whereas PG2 was ineffective.
CA 02692251 2015-06-09
31
Chromatograms from 1% solutions
Comparison of PG1 and 2
NMR analysis of the soluble components needs substantial amount of material.
Therefore, 1%
solutions were produced for semi-preparative gel permeation chromatograms. As
a
comparison to the chromatograms from 0.2% solutions in Fig. 3 are shown the
chromatograms of soluble materials from 1% solutions of PG1 and 2. Although
the detector is
somewhat overloaded, it is perhaps even more clearly seen that in PG2 there
are not as much
intermediate sized soluble components as in PG1.
Comparison of nine Pro gut-type product and four related samples
Nine Progut-type product (PG1-9) and four related samples (C1-4) were prepared
simultaneously and analyzed equally. Therefore, their gel permeation
chromatograms are
comparable. Here, samples were detected at A230, and for proper comparison,
PG1 and 2 were
reanalyzed. The scale of the absorbance axis is adjusted to be equivalent in
all chromatograms
in order to facilitate the comparison of the samples.
The chromatograms of PG1, 3, 4, and 6 look rather similar (Fig. 4, A, C, D, F)
both in shape
and amount of the material. Both PG1 (in bacterial adhesion assay) and PG4 (in
field
experiment with goats) have been shown to be effective. On the other hand,
PG2, 5, 7, and 8
.. have less material than the other PG samples (Fig. 4, B, E, G, H). From
these PG2 is known
to be ineffective in bacterial adhesion assay. The data indicates that in a
preferred
embodiment the effective Progut-type product can be predicted by the shape of
the
chromatogram and especially by the amount of intermediate size soluble
material. The
relative amounts of the intermediate size material (eluting at 12-16 ml) can
be calculated as
area from the chromatogram (mAbs units multiplied by ml) and comparing these
values
(Table 1) confirms the estimations of the differences between Progut-type
product samples.
The large size (eluting at 6-12 ml) and the intermediate size (eluting at 12-
16 ml) material has
been collected for NMR analysis.
CA 02692251 2015-06-09
32
In related samples the amounts of intermediate size and even large material is
much less than
in Progut-type product samples (Fig 4, J, K, L, M). The total amount of
soluble material in
Alphamune alpharma (C3) and Bio-Mos (C4) (Fig 4, L, M, respectively) looks
minor when
compared to Progut-type product samples, which can be seen also in Fig. 1. In
Agrimos (Cl)
and especially in Ascogen (C2) the total amount of soluble material is
comparable to Progut-
type product, but most of it is low molecular weight size material (Fig. 4, J,
K). The low
molecular weight size material is not good in inhibiting bacterial adhesion,
although it might
have some other beneficial properties.
Table 1. Relative amounts of components from chromatograms in Fig. 4. The area
was
calculated as mAbs units multiplied by ml (here, the areas are combined from
three
semipreparative chromatograms).
Sample Fig. 4 Area (12-16 ml) Area (6-14 ml)
PG1 A 17600 22805
PG2 B 6400 7189
PG3 C 14900 21685
PG4 D 12400 22300
PG5 F 7700 11899
PG6 F 10000 16429
PG7 G 5600 9573
PG8 H 2800 6474
Agrimos J 7100 2445
Ascogen K 14500 6724
Alphamune L 1100 1593
Bio-Mos M 2400 1384
Comparison offive Pro gut-type product samples
Progut-type product samples PG10-14 were prepared similarly for gel permeation
chromatography as the samples of Fig. 4. Therefore, the chromatograms of
figures 4 and 5 are
CA 02692251 2015-06-09
33
comparable. Although no information of the bioactivities of the PG10-14 is
available, these
chromatograms imply that these (PG10-14) Progut-type product batches should
work well,
because in all samples there are substantial amounts of soluble material that
largely consists
of intermediate to high molecular weight compounds. The large size (eluting at
6-12 ml) and
the intermediate size (eluting at 12-16 ml) material has been collected for
NMR analysis.
Acid hydrolyzed brewery yeast and its homogenized version
Brewery yeast solution was homogenized by an industrial pressure homogenizator
and
samples of both brewery yeast solution and its homogenized version were
hydrolyzed by
.. Progut-type product process acid hydrolysis as described in Materials and
Methods. In order
to isolate samples for NMR by semipreparative gel permeation chromatography
the detector
was overloaded and chromatograms comparable to Figs 4 and 5 are not available.
However,
analytical gel permeation chromatograms were run (Fig. 6), and the profiles of
the
chromatograms mimics that of PG1 (Fig. 2A). Comparison of the areas in the
chromatograms
of Fig. 6A and B indicates that the homogenization increases solubility by
15%.
Samples prepared for bacterial adhesion tests
Higher solubility of Progut-type product is needed for dosing it among liquid
feed, most
preferably in drinking water. Ten sample candidates were chosen aiming to new
water-soluble
Progut-type product. These samples were prepared in amounts enough for
bacterial adhesion
tests, their gel permeation chromatograms are presented in Fig. 7. (The
experimental
processes are presented in Materials and Methods of Example 2.) The samples
were:
1. Brewery yeast treated with glucanex and process acid hydrolysis, BY G (Fig.
7 A)
2. Homogenized brewery yeast treated with glucanex and process acid
hydrolysis, HBY G
.. (Fig. 7 B)
3. Brewery yeast treated with glucanex and savinase, followed by process acid
hydrolysis, BY
G+S (Fig. 7 C)
4. Homogenized brewery yeast treated with glucanex and savinase, followed by
process acid
hydrolysis, HBY G+S (Fig. 7 D)
CA 02692251 2015-06-09
34
5. Brewery yeast treated with 1 M H3PO4, BY 1M (Fig. 7 E)
6. Homogenized brewery yeast treated with I M H3PO4, HBY 1M (Fig. 7 F)
7. Brewery yeast treated with glucanex and pectinase, followed by process acid
hydrolysis,
BY G+PE (Fig. 7 G)
8. Homogenized brewery yeast treated with glucanex and pectinase, followed by
process acid
hydrolysis, HBY G+PE (Fig. 7 H)
9. PG1 treated with pectinase, PG1 PE (Fig. 7 I)
10. PG1 treated with pronase, PG1 PR (Fig. 7 .1)
Five of the candidates for new water-soluble Progut-type product (samples 1,
2, 5, 6, and 9)
were finally chosen for bacterial adhesion tests. Treatment of brewery yeast
with glucanex
and with 1 M H3PO4 yielded material with the best activity in bacterial
adhesion assay
performed similarly as for old Progut-type product testing process.
Interestingly, the chromatograms of brewery yeast and its homogenized version
after
enzymatic treatment are rather similar. On the contrary, more soluble,
intermediate sized
material is found in the homogenized brewery yeast treated with 1 M 113PO4
than in non-
homogenized sample (Fig 7, F versus E).
Water-soluble Pro gut-type product
.. In order to test the effectivity of 1 M H3PO4 treated brewery yeast on
field, this was produced
in industrial scale and the product was named as water-soluble Progut-type
product (PG WS).
Another version of PG WS was also produced by introducing emulgator, and this
was named
PG WS+E. Their solubilities were analyzed by gel permeation chromatography and
for easy
comparison, PG1 was analyzed in the same set of experiments (Fig. 8). When
comparing the
chromatograms of PG (Fig. 8 A) and PG WS (Fig. 8 B), and relative amounts of
material
calculated from them (Table 2), it can be concluded that there are over 30%
more soluble
material in PG WS. Specifically, the relative amount of very large size
material (eluting at 6-9
ml) has increased substantially, 60%. However, the relative amount of
intermediate size
material (12-16 ml) is approximately equal. Hence, the higher concentration of
H3PO4 in PG
WS production appears to break down the insoluble part just enough to make it
soluble to
CA 02692251 2015-06-09
water. Although the product is not completely soluble, the change is high
enough to allow PG
WS to be delivered as liquid feed among drinking water.
Another sample was prepared by a longer (15 hour) hydrolysis (PG 15h) in
otherwise normal
production process. The gel permeation chromatogram of PG 15h (Fig. 8 D)
implies that the
5 product is similar to PG1. NMR analysis will reveal whether there are
changes in structures of
the components.
Table 2. Relative amounts of material from chromatograms in Fig. 8A and B. The
amount of material is specified as the area from the chromatograms as
calculated mAbs units
10 multiplied by ml.
Elution PG1 PG-WS PG1 PG-WS
volume (area) (area) (relative amount) -- (relative amount)
6-16 ml 2454 3226 1.00 1.32
15 6-12 ml 1846 2515 1.00 1.36
12-16 ml 607 711 1.00 1.32
6-9 ml 1071 1727 1.00 1.61
9-16m1 1383 3225 1.00 1.31
20 NMR-analysis of intermediate size components in Progut-type product
samples
The most prominent signals in the intermediate size fraction NMR analysis can
be assigned to
H-1 of a-glycosidic carbohydrate chains. Considering the biological origin of
the material
analyzed, a-glucan chains and a-mannosidic chains are the expected source of
the signals.
The spectra also show signals that originate from H-1 of p-glycosidic units.
These signals are
25 expected to originate from various 13-glucose residues. Carbohydrate
oligomers containing
such units are expected to be produced in the process of the present invention
from e.g. beta-
glucans of yeast and barley.
CA 02692251 2015-06-09
36
Conclusion
Progut-type product samples and related samples from main producers were
analyzed for their
solubility and their gel permeation chromatography profiles are generated.
From these results,
it looks like that the relative amount of soluble material of equally
processed samples implies
the effectivity of Progut-type product in question as animal feed. The amount
of both large
and intermediate size material seems to be particularly important. In all of
the related samples
the amount of large and intermediate size material is clearly lower than in
Progut-type product
samples. In some of the related samples most of the soluble material is of low
molecular
weight size, which is not likely to be effective in inhibiting bacterial
adhesion.
The invention is directed to isolation of the soluble components shown in
these gel
permeation chromatograms and optional further fractionation of the materials
and more
detailed chemical analysis e.g. by NMR for the isolated and/ fractionated
materials..
The invention is especially directed to the intermediate sized material and
its relative amount
as important component for activity. The invention is further directed to the
large sized
material and its relative amount as important component for activity.
EXAMPLE 2
Materials and Methods
Materials
ProgutTM (PG)- type product samples from Suomen Rehu
PG1; PG2; PG 15h, PG hydrolyzed for 15 h; PG WS, PG water soluble; PG WS E+,
PG water
soluble with emulgator.
PG1 has been shown to work well, whereas PG2 was not so effective on bacterial
adhesion
assays.
Whole brewery yeast samples
Brewery yeast samples used in the present experiments had 20% of dry
substance, on average.
CA 02692251 2015-06-09
37
Hydrolysis with acid
Phosphoric acid
The main acid hydrolysis to the whole brewery yeast -solution with H3PO4 is
similar to the
hydrolysis used in Progut-type product manufacturing process: pH is adjusted
to 2.4 by
H3PO4 (concentrated, 87%), and incubated at 80 C for four hours. This acid
hydrolysis is
referred hereinafter as 'process acid hydrolysis' in text.
Acid hydrolysis with higher concentrations of1-13PO4 were performed with 0.3
M, 0.5 M, 1
M, and 2 M H3PO4 either at 80 C or at 100 C, for four hours.
Hydrochloric acid
.. Acid hydrolysis with HC1 was performed with 0.3 M, 0.5 M, 1 M, and 2 M 1-
lC1 at 80 C, for
four hours.
Sulfuric acid
Acid hydrolysis with H2SO4 was performed with 0.3 M, 0.5 M, 1 M, and 2 M H2SO4
at 80 C,
for four hours.
Solubility experiment
0.2% water solution was prepared either from Progut-type product samples or
the brewery
yeast -solution (i.e. 500 I of the reaction mixture, containing 100 mg dry
weight material,
was diluted up to 50 ml with H20). This was incubated at room temperature for
2-5 hours
under gentle mixing. It was shown that the duration of incubation was not
relevant for the
solubility. The mixture was centrifuged (4000 rpm for 20 min) and the weight
of the
precipitate was measured after lyophilization.
Enzymatic treatments
Pronase
20 mg of pronase (Streptomyces griseus, 48 U / mg, Sigma) for 5 ml of brewery
yeast -
solution / 20% Progut-type product solution, 5 mM CaCl2, incubation at 37 C
for five hours.
The process acid hydrolysis was performed either before or after the enzymatic
treatment. The
effect of pronase was analyzed by the solubility experiment.
CA 02692251 2015-06-09
38
Savinase
ml of brewery yeast -solution / 20% Progut-type product solution, pH adjusted
to 10 by
NaOH, 4 or 20 Ill of savinase (protease from Bacillus sp, 16 mU /ill, Sigma),
incubation at
37 C for five hours. The process acid hydrolysis was performed either before
or after the
5 enzymatic treatment. The effect of savinase was shown by the solubility
experiment.
Glucanex
The effect of glucanex (lysing enzymes from Trichoderma harzianum, 1.18 U / g,
Sigma) to
the solubility of brewery yeast -solution was studied by varying the amount of
glucanex or the
temperature in the reaction. For 5 ml of brewery yeast -solution 5-100 mg of
glucanex was
added and incubated at 30, 37 or 50 C for five hours. The process acid
hydrolysis was
performed after the enzymatic treatment. The effect of glucanex was shown by
the solubility
experiment.
Pectinase
mg of pectinase was added (Aspergillus niger, 1 U / mg, Calbiochem) for 5 ml
of brewery
15 yeast -solution or 20% Progut-type product solution and incubated at 37
C for five hours. The
process acid hydrolysis was performed either before or after the enzymatic
treatment. The
effect of pectinase was shown by the solubility experiment.
Endoglucanase
200 lig of endoglucanase (endoglucanase I from T reesei, from VTT) for 5 ml of
brewery
20 yeast -solution, incubation at 37 or 50 C for five hours. This reaction
was performed only
together with either glucanex or both glucanex and savinase (see below).
Combined enzymatic treatments
Combined effect of glucanex and savinase: First reaction by glucanex as
described, and then
savinase at pH 10 as described. The process acid hydrolysis was performed
after the
enzymatic treatments, after which the effect of the enzymes was shown by the
solubility
experiment.
Combined effect of glucanex and endoglucanase: Concomitant reactions by
glucanex and
endoglucanase, at 37 or 50 C, as described. The process acid hydrolysis was
performed after
CA 02692251 2015-06-09
39
the enzymatic treatments, after which the effect of the enzymes was shown by
the solubility
experiment.
Combined effect of glucanex, endoglucanase, and savinase: First the reaction
by glucanex and
endoglucanase, at 37 or 50 C as described, and then the savinase at pH 10 as
described. The
process acid hydrolysis was performed after the enzymatic treatments, after
which the effect
of the enzymes was shown by the solubility experiment.
Results
Each series of experiments included a control reaction, which mimicked the
production
process of the original Progut-type product, i.e. the brewery yeast -solution
was treated with
the process acid hydrolysis as described in Materials and Methods.
The increase in the solubility of the components after the enzymatic and / or
acid hydrolysis
experiments were measured inverse fashion: Because the dry weight of the
soluble
components was rather impossible to measure, the diminishing of the insoluble
components
was measured instead.
Effect of pronase
Progut-type product samples were treated with pronase as described in
Materials and
Methods. PG1 is, according to bacterial adhesion inhibition tests, effective
as animal feed and
seems to have better solubility than PG2. The solubility of both Progut-type
product samples
increases considerably by pronase treatment as seen in Fig. 9 where the
amounts of insoluble
material is presented (the original dry weight material in these samples was
100 mg).
In the next series of experiments the pronase digestions with PG1 and PG2 were
repeated, and
.. as shown in Fig. 10, the results are rather similar.
In this series of experiments also the effect of pH in pronase digestion with
brewery yeast was
studied. Digestions were performed at pH 5 (the pH of intact brewery yeast
solution) and at
pH 8, and followed by acid hydrolysis. The change in pH during incubation did
not cause any
significant difference in solubility (data not shown).
CA 02692251 2015-06-09
The activity of pronase incubated either before or after acid hydrolysis was
also studied. The
results in Fig. 10 show that pronase is more effective after acid hydrolysis
than before it, most
probably implying that after acid hydrolysis the proteins are denaturated and
more accessible
to protease.
5 Hence, pronase would increase the solubility of Progut-type product even
if it is used before
acid hydrolysis. Considering the Progut-type product production process, this
is beneficial,
because the acid hydrolysis would destroy pronase and the product itself would
not have
enzymatic activity left when used as animal feed.
Comparing the solubility results of Progut-type product or brewery yeast (Fig.
10) it seems
10 that the original, industrial Progut-type product producing process (1)
is more effective in
producing more soluble product and, (2) this product is more vulnerable to the
action of
pronase than the lab-scale acid hydrolysis process for intact brewery yeast.
Effect of savinase
In order to examine the reactivity of another protease with Progut-type
product, savinase
15 (protease from Bacillus sp.) was chosen, a basic protease which is in
industrial production.
When tested with Progut-type product, savinase decreased the amount of
insoluble material
almost in half (Fig. 11). However, the effectivity of pronase (Fig. 10) seems
rather better:
While pronase diminished the amount of insoluble material up to 22% (PG1), in
savinase
treated PG1 there was 53% left. In contrast to the action of pronase, the
amount of insoluble
20 material is independent whether savinase is used before or after the
process acid hydrolysis
(cf. Figs 10 and 11, experiments with brewery yeast).
Because savinase is an industrial enzyme, it could be used at reasonable
costs. However, the
use of savinase is not as practical as the use of pronase: As savinase is a
basic protease, the
pH has to be adjusted to 10 in order to get effective reaction. This means
that after
25 neutralization (regardless whether the savinase is performed before or
after the process acid
hydrolysis) the sodium phosphate concentration of the product is substantial.
CA 02692251 2015-06-09
41
Effect of pectinase
Pectins are large, heterogeneous, and negatively charged cell-wall
polysaccharides. Industrial
pectinase is a lysing enzyme of pectin and, in addition, contains several
other enzymatic
activities as well. Therefore, it was thought that the pectinase treatment
could be effective in
Progut-type product solution. Indeed, pectinase was shown to be more effective
than savinase,
but not as effective as pronase in producing more water-soluble Progut-type
product (Figs 10,
11, and 12). For example, the dry weight of insoluble material in PG1
diminished with
pronase up to 22% and with pectinase to 34%, leaving 8.5 or 15 mg insoluble
material,
respectively. In contrast to the proteases pronase and savinase, pectinase
treatment is effective
with brewery yeast solution only after the procedure acid hydrolysis (Fig 12).
Effect of glucanex
In order to analyze the impact ofp-glucans to the solubility of Progut-type
product, p-
glucanase treatments were performed. Glucanex (lysing enzymes from Trichoderma
harzianum) was chosen, because it was known as cost-effective yeast cell wall
glucan
.. hydrolyzing enzyme. Glucanex is known to contain also cellulase, protease,
and chitinase
activities. First, the effect of various amounts of glucanex was studied at 30
C. It was clearly
shown that small amounts of glucanex did not increase the solubility of
brewery yeast
substantially. However, with 100 mg / 5 ml of brewery solution, the amount of
insoluble
material decreased up to 46% as shown in Fig. 13. In the second reaction
series the effect of
temperature was studied and it was performed with brewery yeast that had been
at +4 C for a
one month, making it a bit more liquid. Increasing the incubation temperature
by 7 C (from
C to 37 C) increased the solubility clearly (the insoluble material from 64%
to 54%). In
contrast, when the temperature was raised to 50 C, the amount of insoluble
material
decreased only 26%, implying that the enzyme did not tolerate such high
temperatures. At
25 37 C glucanex produces approximately the same reduction in insoluble
material amount as
pronase and pectinase (cf. Figs 10, 12, and 13).
CA 02692251 2015-06-09
42
Effect of combined enzyme treatments
Protein and polysaccharide degrading enzymes were rather effective in lowering
the amount
of insoluble material in Progut-type product or brewery yeast solutions, as
shown above.
However, neither of these enzyme-types was alone able to produce water-soluble
product.
Next was studied whether the reactivities of proteases and e.g. glucanases are
combinatory,
i.e. is soluble product producible by combined action of these enzymes.
Glucanex and savinase
Glucanex and savinase are both cost-effective industrial enzymes, and
therefore chosen to be
tested for combined reactivity. When comparing the effect of glucanex alone
(Fig. 13) or
savinase alone (Fig. 11) to their combined action, it is clearly seen that
they work more
effectively together (Fig. 14): The insoluble material was reduced with
glucanex (20 mg,
37 C) treatment alone by 47% and with savinase alone (41.11, 37 C) by 32%,
while in their
combined reaction the reduction was 77% (i.e. only 12 mg of original dry
weight material was
left insoluble). However, even in the best reaction performed (glucanex 100 mg
at 30 C and
savinase 4 at 37 C) there are still 8.5 mg out of the 100 mg dry weight
material originally
in brewery yeast solution left. Savinase was shown to be less effective than
pronase or
pectinase and glucanex approximately equally effective as pronase and
pectinase (see above).
The combined action of glucanex and savinase with brewery yeast solution gives
far better
results than with pronase and pectinase, and actually resembles the
effectivities of pronase
and pectinase with Progut-type product.
Endoglucanase combined with glucanex and/or savinase
In order to improve the polysaccharide degradation, the effectivity
endoglucanase
(endoglucanase I from T. reesei) in combination with glucanex and savinase was
studied.
Experiments of glucanex and endoglucanase treatment (Fig. 15) and glucanex
alone (Fig. 13)
show no additive effect; the amounts of insoluble material compared to control
are 54% and
53%, respectively. Similarly, with glucanex and savinase, in these experiments
the
endoglucanase does not improve the solubility (with EG 22% and without 23% of
insoluble
material versus control).
CA 02692251 2015-06-09
43
Effect of acids
In order to establish the difference between the solubilizing effect of H3PO4
compared to
other acids, two strong acids, HC1 and H2SO4, were chosen for acid hydrolysis
experiments.
The effect of higher acid concentrations to the solubility of brewery yeast
solution was also
studied.
H3PO4 - effect of increasing concentration with or without savinase
Figure 16 shows the results of two sets of experiments with brewery yeast
solution. Clearly,
higher concentrations of 113PO4 (0.3 M, 0.5 M, and 1 M, at 100 C) increase the
solubility of
the product (Fig. 16, first three column pairs). Savinase treatment with
brewery yeast solution
combined with acid hydrolysis at 80 C, in higher concentrations of H3PO4 (0.3
M, 0.5 M, 1
M, and 2M) results in rather similar solubility as the acid hydrolysis at 100
C.
HC1
The acid hydrolysis of brewery yeast solution with variable HC1 concentrations
(Fig. 17)
shows rather similar effectivity as hydrolysis with H3PO4.
H2SO4
The acid hydrolysis of brewery yeast solution with increasing H2SO4
concentrations (Fig. 18)
compared with hydrolysis by H3PO4 (Fig. 16) indicates that the acids give
fairly similar
solubilities. Interestingly, the solubility of the acid hydrolysis product
decreases with 2 M acid
compared to 1 M. 2 M H2SO4 might precipitate components from the brewery yeast
solution,
because it is such a strong acid.
Effect of homogenization
In order to analyze whether mechanical treatment of brewery yeast solution
would improve
the effect of acid hydrolysis, a sample of brewery yeast was homogenized by an
industrial
homogenizator. There is a 10% increase in solubility when compared to the 1 M
acid
CA 02692251 2015-06-09
44
hydrolysis results of homogenized and normal brewery yeast (Fig. 19, brewery
yeast insoluble
material 75% left and homogenized brewery yeast 65% left comparing to process
hydrolysis).
In contrast, as shown in Fig. 20 homogenization has only a minor effect to the
degrading
effectivity of enzymes glucanex, savinase and pectinase.
Comparison of PG, PG WS and PG WS E+
According to these solubility results presented here, five samples were chosen
to be prepared
for bacterial adhesion inhibition experiments. These samples are:
1. Brewery yeast solution with glucanex treatment and process acid hydrolysis,
2. Homogenized brewery yeast solution with glucanex treatment and process acid
hydrolysis,
3. I M H3PO4 acid hydrolysis to brewery yeast solution,
4. 1 M H3PO4 acid hydrolysis to homogenized brewery yeast solution, and
5. PG1 treated with pectinase.
They all gave good results in bacterial adhesion assays (performed similarly
as in old Progut-
type product testing process), glucanex treated sample being the most
effective. However,
because the I M H3PO4 acid hydrolysis -product was almost as effective it was
chosen to be
produced for field experiments.
This water-soluble Progut-type product (PG WS) and water-soluble Progut-type
product with
emulgator (PG WS+E) were produced in industrial process and samples from them
were
studied for their solubility. Figure 21 shows the solubilities of water-
soluble Progut-type
product with and without emulgator in comparison to PG1 and 2. The amount of
insoluble
material has decreased by 40% when comparing PG1 and PG WS. On the other hand,
it seems
that the emulgator does not increase the solubility when compared to the
solubility of PG WS.
In addition, a sample of overhydrolyzed Progut-type product was brought for
analysis. The
solubility experiment of this 15 hours hydrolyzed Progut-type product showed
that there was
almost equal amount of insoluble material left when compared to PG1. Further
analysis
should be done in order to be able to consider whether there has been e.g.
overdegradation.
CA 02692251 2015-06-09
Conclusions
The 1 M H3PO4 hydrolysis of brewery yeast solution in process production
produces a
product that can be delivered to animals as a component of drinking water.
This means that
the amount of insoluble material left in the water-soluble Progut-type product
(26%) is small
5 enough that it will stay in liquid during the delivery process to
animals. This procedure
producing the PG-WS has increased the solubility remarkably, from 42% of
insoluble
material of current Progut-type product product to 26% of PG-WS.
Enzymatic treatments combined with process acid hydrolysis of either Progut-
type product or
brewery yeast solution produced even more soluble products than above
mentioned 1 M
10 H3PO4 hydrolysis alone. At the best the amount of insoluble material was
diminished to 10%
when treated with pronase or combined action of glucanex and savinase.
EXAMPLE 3
15 Solubility of Progut-type product, novel soluble product and competitors
in water
The hydrolysis process was developed further to produce Progut type soluble
product,
referred as Progut type Soluble, which can be used in animal feeding as liquid
mixtures in
automated feeders without delivery problems. The solubility of Progut-type
product is on
20 average about 50% (n=9) while the Progut type Soluble product has a
solubility over 70%.
The competing products all show solubilities less than 40% (Fig. 23).
Features of the Progut type Soluble product
25 Concerning the health and well-being of the animals, the biologically
relevant materials in
Progut-type product and other yeast products are thought to be soluble poly-
and
oligosaccharides. Here, in 1% or more diluted solutions all oligosaccharides
are soluble. The
insoluble part consists of cell wall components, i.e. primarily of insoluble
polysaccharides and
proteins. In gel-permeation chromatography (GPC) the soluble poly- and
oligosaccharides as
CA 02692251 2015-06-09
46
well as peptides (also referred to in this report as "middle-size material")
elute at 6-14 ml, and
their relative amounts are measured at 214 nm.
The modified hydrolysis process of Progut type Soluble product yields almost 2-
fold increase
in the middle-size material and the amount detected in the further processed
novel Progut type
Soluble product is almost three times higher (Fig. 25 and 26). The invention
also revealed
isolated practically totally soluble product referred as Progut type product
Water Soluble.
The amount of poly- and oligosaccharides and peptides is substantially lower
in three
competitor products (Fig. 27 and 28).
Correlation of the soluble material with bacterial adhesion analysis
The biological activity of Progut-type product is proportional to the amount
of middle-size
material. Fig. 29 shows that a higher amount of poly- and oligosaccharides and
peptides leads
to a higher activity in bacterial adhesion. It is also evident that the
competitor products
carrying low amounts of middle-size material show much lower E. coli bacterial
adhesion
(Fig 30).
Monosaccharide analysis ¨ comparison of the mannose content
Mannans and mannooligosaccharides in yeast products are believed to be
bioactive
components. The mannose content of the soluble poly- and oligosaccharide
fraction was
therefore measured and as shown in Fig. 31, Progut-type product products have
clearly more
soluble mannooligosaccharides than competitive products.
The mannose content was also compared to the E. coil bacterial adhesion
activity. It was
found that the correlation between the mannose amount and the bacterial
adhesion activity is
not straightforward (Fig. 32). It is therefore hypothesized that not all
mannose poly- and
oligosaccharides show similar bacterial adhesion activity, but certain
structures show higher
bioactivity.
CA 02692251 2015-06-09
47
NMR analysis of soluble components
'H NMR analysis is able to reveal structural characteristics of
mannooligosaccharides in
Progut-type product and other yeast products. Fig. 33 shows the NMR analysis
of Progut-type
product sample. The structural details of a typical yeast mannan saccharide
and their
characteristic NMR peaks are shown in the inset.
By comparing the NMR spectra of Progut-type product and the three competitor
products
(Fig. 34), it can be concluded that the relative amount of terminal Manal -3
units (blue marks
in Figs 33 and 34) is clearly higher in Progut-type product. Some E.coli
strains (harmful to
gut health) have been shown to bind preferentially to Manal -3 structures in
mammals. The
increase of oligosaccharides with terminal Manal-3 units is a consequence of
the Progut-type
product process hydrolysis step.
Details of the 1H NMR analysis
The NMR samples have been divided into two categories according to their
saccharide
composition.
Low molecular weight Mannopolysaccharide/mannose oligosaccharide containing
samples
The lineshapes/widths of saccharide signals suggest that the saccharides are
fairly large. The
anomeric 1H signals of the constituent mannose units have been assigned based
on the
published data for higher mannan oligosaccharides. The following manno-
oligosaccharide
fragments have been identified. The mannose unit corresponding to the capital
letter is
bolded. The relative concentration of the different mannose residues in each
sample is given
in Table 1. The integration was performed using peak heights and the signal
for A was given
the value 1. According to integration, the concentration of a terminal a-D-
Manp-(1-3)-a-D-
Manp-(1-2) and other common mannose epitopes is higher in PG samples compared
to the
samples from competitors, furthermore the relative proportion of a-D-Manp-(1-
3)-a-D-
CA 02692251 2015-06-09
48
Manp-(1-2) epitope B to internal a-D-Manp-(1-2) epitope A is is higher in the
. All of these
samples also contain starch as indicated (+) in Table 3. The integration of
key Mannose signal
indicates that the starch content is smaller in the PG type samples.
List of specific monosaccharide structures corresponding to mannose NMR
signals A-E
A)
-a-D-Manp-(1-2)-a-D-Manp-(1-2)-a-D-Manp-
B)
a-D-Manp-(1-3)-a-D-Manp-(1-2)-a-D-Manp-
C)
-a-D-Manp-(1-6)-a-D-Manp-(1-6)-a-D-Manp-
I
a-D-Manp-(1-2)+
D)
-a-D-Manp-(1-2)-a-D-Manp-(1-6)-a-D-Manp-
E)
-a-D-Manp-(1-6)-a-D-Manp-(1-2)-a-D-Manp-
and
-a-D-Manp-(1-6)-a-D-Manp-(1-6)-a-D-Manp-
I
a-D-Manp-(1-2)+
and
a-D-Manp-(1-3)-a-D-Manp-(1-2)-a-D-Manp-
Table 3. II-I-NMR signals of mannooligosaccharide fragments and the relative
concentrations
of different mannose residues. In the name of the sample 'large' indicates
large size
components from the gel permeation chromatography, eluting at 6-12 ml.
CA 02692251 2015-06-09
49
NMR sample Starch Manno-oligosacharide fragments
A B C D E
5.302 ppm 5.144 ppm 5.118 ppm 5.096 ppm 5.048 ppm
PG1 large + 1 1.5 0.9 0.8 1.3
PG2 large + 1 1.4 0.8 0.7 1.3
PG4 large + 1 1.3 1 0.8 1.3
PG 15h large + 1 1.5 1 1 1.5
PG S large + 1 1.3 1 1 1.4
PG WS large + 1 1.4 1.1 1.1 1.6
PG S +E + 1 1.4 0.8 0.8 1.4
large
PG10 large + 1 1.4 1 1 1.5
PG11 large + 1 1.3 0.9 0.8 1.3
PG12 large + 1 1.4 0.9 0.8 1.4
-
PG13 large + 1 1.6 0.8 0.8 1.5
PG14 large + 1 1.7 0.9 0.9 1.5
Agrimos + 1 >1" 1.3 1.4 2.1
large
Ascogen + 1 1.1 1 1 1.2
large
Alphamune + 1 1.1 0.8 0.8 1.1
large
Bio-Mos + 1 0.9 0.9 0.8 1
large
'difficult to assign due to background but clearly smaller than 5.302
Starch oligosaccharide containing samples
The following samples contain starch oligosaccharides as the only identifiable
saccharide
component: PG1 intermediate (eluting from GPC at 12-16 ml), P02 intermediate,
PG3
intermediate, PG4 intermediate, PG6 intermediate, PG7 intermediate, PG8
intermediate, PG9
intermediate, PG 15h intermediate, PG10 intermediate, PG11 intermediate, PG12
intermediate, PG13 intermediate, PG14 intermediate, Ag intermediate, As
intermediate, Al
intermediate, and BM intermediate.
The assignment is based on the presence of the signals at 5.409 ppm, 4.972
ppm, 5.231 ppm
and 4.645 ppm, corresponding to the anomeric His of [a-(1-4)G1cp] -chain, a-(1-
6)-Glcp
branch point and the reducing end a-D-Glcp and J3-D-Glcp, respectively.
CA 02692251 2015-06-09
There are also several samples which contain possibly marmooligosaccharide
fragments in
addition to the starch oligosaccharide main component. Identification of these
molecules
requires further investigation.
In NMR spectra of samples PG1 intermediate, PG S intermediate, PG S+E
intermediate, and
5 PG WS intermediate signals corresponding to terminal fragments a-D-Manp-
(1-3)-a-D-
Manp-(1-2)-a-D-Manp- and a-D-Manp-(1-2)-a-D-Manp-(1-2)-a-D-Manp- were present.
Low starch amounts
Table 4 includes quantitation of starch in the large saccharide fraction by
NMR. In a preferred
10 embodiment the invention is directed to saccharide fractions (6-12 min
and optionally also
oligosaccharides) and material according to the invention, wherein the amount
of starch
Glcoc4 epitopes is less than 3.5 fold more that of Manp-(1-3)-a-D-Manp-(1-2),
more
preferably less than 3 fold. The invention further revealed presence reducing
end signals of
starch in the present samples indicating low molecular weight starch chains.
Furthermore the
15 preferred starch according to invention contains modest amounts of Glca6-
branch structures.
The invention is directed to low amounts of starch in context of high amounts
of the preferred
mannose saccharides. It is realized that the starch fragments can be degraded
by amylase type
enzymes. In a preferred embodiment the residual starch material is degraded by
starch
degrading enzymes such as amylase to obtain more pure mannose/glucose
saccharides. The
20 analysis of intermediate Superdex peptide gel filtration fraction
reveals that the amount of
starch oligosaccharides is particularly low in the novel soluble fractions (PG
Water soluble
and Soluble).
Presence of higher amounts of mannose oligosaccharides in the new soluble
preparations
25 The signals of mannose oligosaccharides were more prominent in the
soluble (Soluble and
Water Soluble) saccharide preparations. When comparing the a-D-Manp-(1-3)-a-D-
Manp-(1-
2)-a-D-Manp- signal to starch oligosaccharide signal between soluble
preparations these
signals were at least about 20 % of starch Gle134 signal, in certain
preparations even about 30-
% of the starch signal and about the same amount of total assignable
oligosaccharides. In
30 old process preparations only very minor a-D-Manp-(1-3)-a-D-Manp signals
were observed
CA 02692251 2015-06-09
51
and these were only a few %, typically less than about 5 % of the starch
signal. The
intermediated fraction comprising larger oligosaccharides eluting between 12-
16 min
comprises most of the oligosaccharides except the smallest ones (disaccharides
and probably
part or trisaccharides) but not monosaccharides. It is realized, that presence
of smaller
mannose oligosaccharides is not likely in the samples. The amount of the
intermediate
fraction (superdex peptide 12-16) is substantial part of the total saccharide
type material as
indicated by the gel filtration profiles, estimated to be about 20-50 % of
total saccharides.
Therefore the samples include at least about 4 % -30 %, more preferably at
least about 5- 30
%, even more preferably at least about 10-30 % mannose oligosaccharides of the
total
saccharides. The amount of mannose oligosaccharides of the total mannose
comprising
saccharides is about 10-60 % more preferably 20-60 % based on the mannose and
glucose
content of the sample.
The mannose oligosaccharides in the preparations are highly enriched with the
terminal
Mana3-epitope, which is the major mannose signal in the preparations,
indicating enrichment
of the novel bioactive mannose saccharide inhibiting mannose binding
pathogens.
The data reveals that the actual major mannose oligosaccharides with lower
molecular weight
eluting between 12-16 minutes are effectively produced by the present
optimized method to
produce soluble , but not other methods including previous progut methods or
by the
competing method.
Surprisingly the competitor materials appears not to contain significant
amounts of mannose
oligosaccharides, though some of these are advertised as manno-
oligosaccharides. It appears
that effective production of mannose oligosaccharides from yeast is not easy
task despite the
efforts of many companies.
The residual mannose materials of competitors appear as high molecular weight
poorly
soluble materials as demonstrated also by the very broad and weak NMR signals
in
comparison to more narrow and smooth signals of the materials according to the
present
invention. The invention is in a preferred embodiment directed to novel
saccharide material
CA 02692251 2015-06-09
52
according to the invention producing NMR spectrum with essentially similar
with regard to
the mannose signals A-E and Glcbeta-signals according to the invention,
including preferably
similar peak width, and /or similar peak integrals and heights and similar low
amounts of
starch signals and/or other impurities such as impurity signal at about 4.7
ppm including
possible non-carbohydrate material.
References for NMR analysis:
Kath, F., and Kulicke, W-M (1999) Die Angewandte Makromoleculare Chemie 268,
69-80
Shibata, N., Kojima, C., Satoh, Y., Satoh, R., Suzuki, A., Kobayashi, H., and
Suzuki, S.
(1993) Eur. J. Biochem 217, 1-12
Ikuta, K., Shibata, N., Blake J.S., Dahl M.V., Nelson, R.D., Hisamichi, K.,
Kobayashi, H.,
Suzuki, S., and Okawa Y. (1997) Biochem J. 323, 297-305
In conclusion, Progut-type product contains more terminal Manal-3 units as
shown by 11-1
NMR (Figs 33 and 34) and the mannooligosaccharide content is higher as shown
by the
monosaccharide analysis of soluble material (Fig. 31) than in competitor
products. According
to these results can be concluded that the amount of active
mannooligosaccharides is clearly
higher in Progut-type product than in competitive products.
Assignment of alpha- and beta-Glc comprising materials
The Table 4 shows specific presence GlcP materials in Progut type samples. The
highest
amount of Glcp material was found from the Soluble product indicated by NMR
signal at
about 4.53 ppm. The invention is especially directed to novel Soluble products
when the
amount of Glcp NMR signal at about 4.53 ppm is at least about 80 % (0.8 times
in Table 4) of
Mana3 signal at about 5.14 ppm, more preferably 90 % (0.9 times in Table 4) of
the Mana3
signal. The invention is directed to even equimolar amounts of terminal GlcP
and Mana3-
materials.
It is notable that none of the competing materials contain the Glcp-signal.
The GlcP-signal is
considered to include major amount of GlcP6¨material, this is further
supported by presence
of the signal assignable to GlcP6¨H2 signal at 3.31 ppm. The GlcP-signal also
overlaps the
CA 02692251 2015-06-09
53
region for cerial glucan signal and signal shapes considered to indicate
partial presence of
Glci34 epitope of cerial glucan derived saccharides in the preferred
saccharide material.
Table 4. 1H-NMR signals of oligosaccharide fragments and the relative
concentrations of
different monosaccharide residues. In the name of the sample 'large' indicates
large size
components from the gel permeation chromatography, eluting at 6-12 ml.
NMR sample Oligosaccharide fragments
Manal-3 Glci31 -6a Glc131-3b Glcal-4
Glcal-6 GlcI31-6c
H1 H1 H1 H1 H1 H2
5.144 4.53d 4.76 5.409 4.972
3.31
PG1 large 1 0.7 + 1.7 0.3
yes
PG S large 1 0.9 + 3.0 0.6
yes
PG10 large 1 0.6 + 2.7 0.6
yes
PG11 large 1 0.4 n.d. 1.7 0.6
yes
PG12 large 1 0.3 - 1.2 0.3
yes
PG13 large 1 0.3 n.d. 1.9 0.5
yes
PG14 large 1 0.4 - 1.0
yes
Agrimos 1 - 0.5 0.6 no
large
Ascogen 1 - - 3.6 1.5 no
large
Alphamune 1 - - 8.0 0.1 no
large
Bio-Mos 1 - - 4.0 - no
large
a Note: HI signals of GlcI31-6 and G1411-4 have the same value.
b H1 of GlcI31-3 branch in GlcI31-6 glucan
c The intensity of this signal was not measured, instead is referred whether
it is detected (yes)
or not (no)
d Note. There is rather large background at 4.53 ppm; therefore, the
intensities might be
somewhat overestimated
+ small signal, clearly detectable doublet, too small to be integrated
- no detectable signal
n.d. not determined, the signal arising from H20 overlaps the possibility to
detect this signal
EXAMPLE 4. Animal trials
The novel saccharide preparation PG Water Soluble is fed to test animals as
food supplement
with amounts of 0.3% -3 % of the feed or drinking water using standard methods
used in
CA 02692251 2015-06-09
54
testing Progut (published by Suomen Rehu). Higher weight gains and/or less
diarrhea is
observed than with regular Progut preparations or competing products.
